Which has preferable earnings and valuation, OBI or ABC?

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.65M 2,110.80 -C$424.66K -C$6.00 N/A Abcam £350.40M 0.00 N/A £0.06 N/A

Is OBI or ABC more profitable?

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Ondine Biomedical -1,117.06% -1,411.54% -159.71% Abcam N/A N/A N/A

Does the media favor ONT or OBI?

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 1 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 1.14 beat Oxford Nanopore Technologies' score of 0.51 indicating that Ondine Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Nanopore Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ondine Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OXB or OBI?

Oxford Biomedica currently has a consensus target price of GBX 580.85, suggesting a potential upside of 20.89%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, research analysts plainly believe Oxford Biomedica is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor OXB or OBI?

In the previous week, Oxford Biomedica had 9 more articles in the media than Ondine Biomedical. MarketBeat recorded 10 mentions for Oxford Biomedica and 1 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 1.14 beat Oxford Biomedica's score of 0.40 indicating that Ondine Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 1 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ondine Biomedical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AVCT or OBI?

Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 33.33%. Given Avacta Group's stronger consensus rating and higher possible upside, research analysts plainly believe Avacta Group is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, AVCT or OBI?

Ondine Biomedical has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 3,078.73 -£30.08M -£9.66 N/A Ondine Biomedical C$2.65M 2,110.80 -C$424.66K -C$6.00 N/A

Ondine Biomedical (OBI) Competitors

C$10.75 0.00 (0.00%)

As of 09/23/2026 03:21 PM Eastern

Compare

OBI vs. ABC, ONT, OXB, SLN, and AVCT

Should you buy Ondine Biomedical stock or one of its competitors? Ondine Biomedical's main competitors and comparable companies include Abcam (ABC), Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), Silence Therapeutics (SLN), and Avacta Group (AVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ondine Biomedical compare to Abcam?

Ondine Biomedical (LON:OBI) and Abcam (LON:ABC) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Ondine Biomedical had 1 more articles in the media than Abcam. MarketBeat recorded 1 mentions for Ondine Biomedical and 0 mentions for Abcam. Ondine Biomedical's average media sentiment score of 1.14 beat Abcam's score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Ondine Biomedical	Positive
Abcam	Neutral

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Abcam	N/A	N/A	N/A

32.8% of Ondine Biomedical shares are held by institutional investors. 29.0% of Ondine Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,110.80	-C$424.66K	-C$6.00	N/A
Abcam	£350.40M	0.00	N/A	£0.06	N/A

Summary

Abcam beats Ondine Biomedical on 6 of the 10 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Ondine Biomedical (LON:OBI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Oxford Nanopore Technologies has a beta of 0.964, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.298, suggesting that its stock price is 70% less volatile than the broader market.

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 1 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 1.14 beat Oxford Nanopore Technologies' score of 0.51 indicating that Ondine Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Nanopore Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ondine Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oxford Nanopore Technologies has a net margin of -54.66% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Nanopore Technologies' return on equity of -35.45% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 32.8% of Ondine Biomedical shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 29.0% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Oxford Nanopore Technologies presently has a consensus price target of GBX 198.60, indicating a potential upside of 13.62%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ondine Biomedical has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£235M	7.27	-£175.21M	-£12.50	N/A
Ondine Biomedical	C$2.65M	2,110.80	-C$424.66K	-C$6.00	N/A

Summary

Oxford Nanopore Technologies beats Ondine Biomedical on 9 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and Ondine Biomedical (LON:OBI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Oxford Biomedica has a beta of 1.092, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.298, suggesting that its stock price is 70% less volatile than the broader market.

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 32.8% of Ondine Biomedical shares are owned by institutional investors. 43.3% of Oxford Biomedica shares are owned by company insiders. Comparatively, 29.0% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Oxford Biomedica had 9 more articles in the media than Ondine Biomedical. MarketBeat recorded 10 mentions for Oxford Biomedica and 1 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 1.14 beat Oxford Biomedica's score of 0.40 indicating that Ondine Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	1 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ondine Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oxford Biomedica has a net margin of -23.23% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Biomedica's return on equity of -54.51% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-23.23%	-54.51%	-12.67%
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

Ondine Biomedical has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	3.45	-£143.51M	-£26.92	N/A
Ondine Biomedical	C$2.65M	2,110.80	-C$424.66K	-C$6.00	N/A

Oxford Biomedica currently has a consensus target price of GBX 580.85, suggesting a potential upside of 20.89%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, research analysts plainly believe Oxford Biomedica is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Oxford Biomedica beats Ondine Biomedical on 10 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Silence Therapeutics?

Ondine Biomedical (LON:OBI) and Silence Therapeutics (LON:SLN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Silence Therapeutics has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Silence Therapeutics' return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Silence Therapeutics	N/A	N/A	N/A

Silence Therapeutics has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,110.80	-C$424.66K	-C$6.00	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

In the previous week, Ondine Biomedical had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Ondine Biomedical and 0 mentions for Silence Therapeutics. Ondine Biomedical's average media sentiment score of 1.14 beat Silence Therapeutics' score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Ondine Biomedical	Positive
Silence Therapeutics	Neutral

32.8% of Ondine Biomedical shares are held by institutional investors. 29.0% of Ondine Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Ondine Biomedical beats Silence Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Ondine Biomedical compare to Avacta Group?

Avacta Group (LON:AVCT) and Ondine Biomedical (LON:OBI) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Avacta Group has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.298, meaning that its share price is 70% less volatile than the broader market.

3.1% of Avacta Group shares are owned by institutional investors. Comparatively, 32.8% of Ondine Biomedical shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by insiders. Comparatively, 29.0% of Ondine Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ondine Biomedical has a net margin of -1,117.06% compared to Avacta Group's net margin of -34,584.96%. Ondine Biomedical's return on equity of -1,411.54% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-34,584.96%	-2,983.28%	-21.80%
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

Avacta Group currently has a consensus price target of GBX 99, indicating a potential upside of 33.33%. Given Avacta Group's stronger consensus rating and higher possible upside, research analysts plainly believe Avacta Group is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ondine Biomedical has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	3,078.73	-£30.08M	-£9.66	N/A
Ondine Biomedical	C$2.65M	2,110.80	-C$424.66K	-C$6.00	N/A

In the previous week, Ondine Biomedical had 1 more articles in the media than Avacta Group. MarketBeat recorded 1 mentions for Ondine Biomedical and 0 mentions for Avacta Group. Ondine Biomedical's average media sentiment score of 1.14 beat Avacta Group's score of 0.00 indicating that Ondine Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Avacta Group	Neutral
Ondine Biomedical	Positive

Summary

Ondine Biomedical beats Avacta Group on 9 of the 16 factors compared between the two stocks.

Get Ondine Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBI vs. The Competition

Export

Metric	Ondine Biomedical	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	C$5.59B	C$3.98B	C$7.31B	C$2.89B
Dividend Yield	N/A	3.63%	2.52%	6.22%
P/E Ratio	-1.79	13.88	274.10	366.58
Price / Sales	2,110.80	1,437.48	672.61	90,068.21
Price / Cash	1.99	113.29	77.80	27.89
Price / Book	1,244.98	15.45	10.48	6.42
Net Income	-C$424.66K	-C$22.82M	C$3.49B	C$5.89B
7 Day Performance	4.37%	-1.68%	-0.68%	0.20%
1 Month Performance	-12.24%	-6.15%	-3.18%	6.38%
1 Year Performance	-25.86%	30.67%	15.13%	19.26%

Ondine Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBI Ondine Biomedical	N/A	C$10.75 flat	N/A	-28.3%	C$5.59B	C$2.65M	N/A	N/A	News Coverage Positive News Gap Up
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
ONT Oxford Nanopore Technologies	2.5027 of 5 stars	GBX 156.02 +2.2%	GBX 198.60 +27.3%	+12.9%	£1.53B	£235M	N/A	1,314	Positive News High Trading Volume
OXB Oxford Biomedica	2.2211 of 5 stars	GBX 444 -0.6%	GBX 580.85 +30.8%	-18.0%	£536.85M	£168.74M	N/A	891	News Coverage Earnings Report Gap Up High Trading Volume
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OBI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, ONT, OXB, SLN, and AVCT

How does Ondine Biomedical compare to Abcam?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Summary

How does Ondine Biomedical compare to Silence Therapeutics?

Summary

How does Ondine Biomedical compare to Avacta Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, ONT, OXB, SLN, and AVCT

How does Ondine Biomedical compare to Abcam?

Does the media refer more to OBI or ABC?

Is OBI or ABC more profitable?

Do institutionals & insiders hold more shares of OBI or ABC?

Which has preferable earnings and valuation, OBI or ABC?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Which has more risk and volatility, ONT or OBI?

Does the media favor ONT or OBI?

Is ONT or OBI more profitable?

Do institutionals and insiders have more ownership in ONT or OBI?

Do analysts prefer ONT or OBI?

Which has stronger valuation & earnings, ONT or OBI?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Which has more volatility & risk, OXB or OBI?

Do insiders and institutionals hold more shares of OXB or OBI?

Does the media favor OXB or OBI?

Is OXB or OBI more profitable?

Which has better valuation and earnings, OXB or OBI?

Do analysts recommend OXB or OBI?

Summary

How does Ondine Biomedical compare to Silence Therapeutics?

Is OBI or SLN more profitable?

Which has higher earnings & valuation, OBI or SLN?

Does the media refer more to OBI or SLN?

Do insiders & institutionals have more ownership in OBI or SLN?

Summary

How does Ondine Biomedical compare to Avacta Group?

Which has more volatility & risk, AVCT or OBI?

Do institutionals & insiders hold more shares of AVCT or OBI?

Is AVCT or OBI more profitable?

Do analysts rate AVCT or OBI?

Which has better earnings and valuation, AVCT or OBI?

Does the media prefer AVCT or OBI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools